Fatigue | Page 20 of 31 | SpiritIndia.com

Osteosarcoma :: IDM Pharma’s Mepact, mifamurtide – Junovan in the Treatment of Osteosarcoma

IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted a Marketing Authorization Application (MAA) in eCTD format (electronic common technical document) to the European Medicines Agency (EMEA) for Mepact (mifamurtide for injection), requesting approval for its use in the treatment of patients with newly diagnosed resectable high-grade osteosarcoma following surgical resection in combination with post-operative multi-agent chemotherapy. This announcement follows the October 25, 2006 submission of a New Drug Application (NDA) for Junovan (mifamurtide for injection) to the Food and Drug Administration (FDA) in the United States.

Multiple Sclerosis :: Living with fatigue – a new MS Trust book

The latest book from the MS Trust aims to give people with MS a better understanding of the causes of fatigue and offers some practical suggestions for managing the symptom.

Immunity :: Natural compounds block autoimmune response in diabetes, arthritis

Natural compounds derived from a sea anemone extract and a shrub plant have been found to block the autoimmune disease response in type-1 diabetes and rheumatoid arthritis, according to University of California, Irvine researchers.

Health :: Hormone therapy does not improve quality of life for women

A postmenopausal hormone therapy trial conducted in Estonia indicates that hormone therapy does not improve women’s quality of life. The group receiving hormones and the comparison group showed no differences in general quality of life. Only those women that experienced hot flashes and night-time sweating reported beneficial effects.

Chronic Fatigue Syndrome :: Promoting awareness of Chronic Fatigue Syndrome

The Centers for Disease Control and Prevention (CDC) today launched a national public education and awareness campaign on Chronic Fatigue Syndrome (CFS), a weakening and often devastating illness for millions of Americans. The campaign, called “Get Informed. Get Diagnosed. Get Help”, is designed to increase awareness among clinicians and the public, because 80 percent of Americans afflicted with CFS illness may not know they have it.

Multiple Myeloma :: Long-term therapy in the fight against multiple myeloma cancer

There is no known cure for multiple myeloma, so its diagnosis means high-dose chemotherapy followed by repeated treatments with each relapse of the cancer ? a watch and wait approach. A new approach of providing patients with continuous therapy to keep the cancer at bay was explored by a team of international researchers from France, Switzerland, and Belgium; their findings will be published in the November 15, 2006, issue of Blood, the official journal of the American Society of Hematology.

Health :: New treatment for Pompe disease – Glycogen storage disease type 2

Patients with a potentially fatal disease are being offered the UK?s first treatment for the condition at the Royal Free. Pompe disease is a neuro-muscular disorder caused by an enzyme deficiency. The lysosomal storage disorders unit at the hospital recently began a programme using Myozyme, the first licensed enzyme replacement therapy for this condition.

Diabetes :: Benefit of Gluten-Free Diet in Type 1 Diabetic Children With Celiac Disease

Patients with celiac disease showed clinical improvements with a Gluten-Free Diet, GFD reported in a Denmark study. This study was performed to 1) determine the prevalence of celiac disease in Danish children with type 1 diabetes and 2) estimate the clinical effects of a gluten-free diet (GFD) in patients with diabetes and celiac disease.

Diabetes :: Celiac disease common in kids with type 1 diabetes

Earlier studies suggest that children with type 1 diabetes are more likely to have a subsequent diagnosis of celiac disease. However, research is sparse on the risk of subsequent type 1 diabetes in individuals with celiac disease. We sought to determine the risk of subsequent type 1 diabetes diagnosed before the age of 20 years in children and adolescents with celiac disease in a national, general population-based cohort – Jonas F. Ludvigsson, Department of Pediatrics, ?rebro University Hospital, ?rebro.

Health :: Pharmion enrolled first patient into Vidaza Patient Registry

Pharmion Corporation (Nasdaq: PHRM) announced today the enrollment of the first patient in AVIDA(TM), a registry for patients treated with Vidaza(R) (azacitidine for injectable suspension). Vidaza was approved in May 2004 for the treatment of all five French-American-British (FAB) subtypes of myelodysplastic syndromes (MDS): refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). Myelodysplastic syndromes are a serious and life-threatening group of diseases in which the bone marrow does not function normally, resulting in the production of malformed or immature blood cells.